16 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
44
Isoform-Selective and Stereoselective Inhibition of Hypoxia Inducible Factor-2.

University of Texas Southwestern Medical Center
22
Development of inhibitors of the PAS-B domain of the HIF-2a transcription factor.

University of Texas Southwestern Medical Center
12
Inhibition of hypoxia inducible factor-2 transcription: isolation of active modulators from marine sponges.

National Cancer Institute-Frederick
6
Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2a induced gene expression.

Nci-Frederick
18
Proline Analogues in Drug Design: Current Trends and Future Prospects.

Enamine Ltd.
13
Recent progress in the development of hypoxia-inducible factor 2α (HIF-2α) modulators: Inhibitors, agonists, and degraders (2009-2024).

Hubei Polytechnic University
8
Identification of 3-aryl-5-methyl-isoxazole-4-carboxamide derivatives and analogs as novel HIF-2α agonists through docking-based virtual screening and structural modification.

Zhejiang University
41
Discovery of Cycloalkyl[

Merck Healthcare
11
Discovery of a Potent and Orally Bioavailable Hypoxia-Inducible Factor 2α (HIF-2α) Agonist and Its Synergistic Therapy with Prolyl Hydroxylase Inhibitors for the Treatment of Renal Anemia.

China Pharmaceutical University
6
Inhibitors of Hypoxia-Inducible Factors as Treatment for Cancer.

Therachem Research Medilab
10
3-[(1

Peloton Therapeutics
18
Synthetic approaches and application of representative clinically approved fluorine-enriched anti-cancer medications.

Shengjing Hospital of China Medical University
54
Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385).

Peloton Therapeutics
15
PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALTS THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT

Hana Pharm
29
Cyanopyrrolidine derivatives as inhibitors for DUBs

Mission Therapeutics